Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

NCT04769648 | Unknown Phase 2 FDA Drug

• 1 other identifier: oGvHD-2-SC
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical study seeks to evaluate the safety and efficacy of Pro-ocular™1% topical gel in patients with ocular Graft-versus-Host Disease who wear scleral lenses daily. This vehicle-controlled trial will evaluate the investigational drug's effect on signs and symptoms of ocular Graft-versus-Host Disease and on the hours of daily comfortable and serviceable scleral lens wear.

Conditions

Ocular Graft-versus-host Disease

Keywords

scleral lens; scleral lenses; scleral lens wear

Outcome Measures

Primary Outcomes (1)

• Change in Modified Symptom Assessment in Dry Eye Questionnaire, Global Score for nighttime without scleral lenses.

  0-100 visual analog scale, lower score is a better outcome than a higher score

  12 weeks

Secondary Outcomes (2)

• Change in Central Corneal Staining

  12 weeks

• Change in Blurred or Cloudy Vision in Glia Ocular Surface Disease Symptoms Questionnaire.

  12 weeks

Other Outcomes (9)

• Change in Corneal fluorescein staining using modified NEI scoring.

  12 weeks

• Change in Conjunctival lissamine staining using NEI scoring.

  12 weeks

• Change in Eyelid evaluation using Efron scale with 0.5 steps (with and without scleral lenses).

  12 weeks

Study Arms (2)

Vehicle

PLACEBO COMPARATOR

Drug: Placebo

Pro-ocular™ Topical Gel 1%

EXPERIMENTAL

Drug: Pro-ocular™ Topical Gel 1%

Interventions

Pro-ocular™ Topical Gel 1% DRUG

Pro-ocular™ is a topical gel applied dermally to forehead twice-daily

Pro-ocular™ Topical Gel 1%

Placebo DRUG

Placebo is a vehicle topical gel without active ingredient applied dermally to forehead twice-daily

Vehicle

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female of any race, at least 18 years of age at Visit 1.
• Has had the diagnosis of ocular GvHD (oGvHD) for at least 3 months prior to Visit 1.
• Use of scleral lenses daily in both eyes for at least two months prior to Visit 1 for treatment of oGvHD with planned continuation for use of the same scleral lenses throughout this study.
• Excluding final scleral lens removal of the day, after successful daily insertion, patient feels need to remove or does remove one or both scleral lenses at least once per day due to physical discomfort or visual acuity issues (lenses have debris or deposit build up or vision is foggy, cloudy or blurry).
• Has staining score in central corneal region of ≥ 2 out of 10 in either eye at Visit 1.
• Has Modified SANDE Frequency score of ≥ 35 out of 100 in either eye for both Modified SANDE daytime questionnaire with lenses and Modified SANDE nighttime questionnaire without lenses.
• Has provided verbal and written informed consent.
• Be able and willing to follow oral and written instructions provided in English, with or without assistance and participate in all assessments and visits.
• Has access to telephone necessary for evaluations.
• Had an ophthalmological exam within past year prior to Visit 1.

You may not qualify if:

• Has tested positive from COVID-19 within twenty-eight days prior to Screening.
• Active trigeminal neuritis, trigeminal neuralgia, ocular herpes zoster, facial herpes zoster, ocular herpes simplex, or neurotrophic keratitis at Visit 1.
• History of ocular herpes zoster, facial herpes zoster, ocular herpes simplex, or neurotrophic keratitis within the last 5 years that is not being medically managed including oral antivirals. Patients with a history of herpes simplex virus must be receiving appropriate antiviral therapy.
• History of breast cancer in patient or immediate biological family (parents, siblings and children).
• Eyelid surgery or ocular surgery within the last 12 weeks prior to screening that in the judgment of the clinical investigator will interfere with study assessments.
• Comorbidity with other severe, acute or chronic systemic or ocular condition that in the judgment of the investigator will interfere with study assessments, study participant safety, or study compliance such as active COVID-19 infection.
• Significant change (e.g. discontinuation) in oral corticosteroid dose or corticosteroid-containing eye drops or gels, cyclosporine ophthalmic emulsion or lifitegrast ophthalmic solution within 7 days prior to screening.
• Wears any type of lenses overnight (e.g. scleral lenses, bandage contact lenses).
• Women of childbearing potential who are pregnant, nursing an infant, planning a pregnancy, not receiving an adequate method of birth control, or have a positive urine pregnancy test at Screening. Women of childbearing potential must be willing to use contraception throughout this study.
• Has a known adverse reaction and/or sensitivity to the study drug.
• Prior or current use of Pro-ocular™.
• Unwilling to cease the use of sunscreen on the forehead or eye area.
• Currently using more than one preserved topical medication for glaucoma.
• Currently enrolled in an investigational drug or device study exclusively for ocular GvHD.

Sponsors & Collaborators

• Glia, LLC: lead

Study Sites (1)

BostonSight

Needham, Massachusetts, 02494, United States

Location

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Subjects randomized for week 0 - week 12; subjects, investigators and study staff will be masked through week 24.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: 12 weeks randomized 1:1 active to placebo. At 12 weeks, placebo group crosses over to active drug. At week 24, all subjects can opt in to an open-label phase.

Study Record Dates

• First Submitted: February 21, 2021
• First Posted: February 24, 2021
• Study Start: April 15, 2021
• Primary Completion: August 15, 2023
• Study Completion: October 15, 2023
• Last Updated: March 24, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)